evolent health inc - EVH

EVH

Close Chg Chg %
4.38 -0.17 -3.77%

Closed Market

4.21

-0.17 (3.77%)

Volume: 2.06M

Last Updated:

Jun 5, 2026, 3:59 PM EDT

Company Overview: evolent health inc - EVH

EVH Key Data

Open

$4.40

Day Range

4.13 - 4.44

52 Week Range

2.10 - 12.07

Market Cap

$492.67M

Shares Outstanding

112.48M

Public Float

107.51M

Beta

0.84

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.76

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.80M

 

EVH Performance

1 Week
 
6.84%
 
1 Month
 
0.96%
 
3 Months
 
33.12%
 
1 Year
 
-49.34%
 
5 Years
 
-77.14%
 

EVH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About evolent health inc - EVH

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

EVH At a Glance

Evolent Health, Inc.
1812 North Moore Street
Arlington, Virginia 22209
Phone 1-571-389-6000 Revenue 1.88B
Industry Miscellaneous Commercial Services Net Income -534,510,000.00
Sector Commercial Services Employees 4,200
Fiscal Year-end 12 / 2026
View SEC Filings

EVH Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.243
Price to Book Ratio 1.075
Price to Cash Flow Ratio 11.76
Enterprise Value to EBITDA 11.386
Enterprise Value to Sales 0.676
Total Debt to Enterprise Value 0.78

EVH Efficiency

Revenue/Employee 446,721.19
Income Per Employee -127,264.286
Receivables Turnover 6.055
Total Asset Turnover 0.844

EVH Liquidity

Current Ratio 1.314
Quick Ratio 1.314
Cash Ratio 0.462

EVH Profitability

Gross Margin 15.138
Operating Margin -0.236
Pretax Margin -28.495
Net Margin -28.489
Return on Assets -24.057
Return on Equity -75.472
Return on Total Capital -38.046
Return on Invested Capital -34.524

EVH Capital Structure

Total Debt to Total Equity 238.37
Total Debt to Total Capital 70.447
Total Debt to Total Assets 52.11
Long-Term Debt to Equity 234.675
Long-Term Debt to Total Capital 69.354
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Evolent Health Inc - EVH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.35B 1.96B 2.55B 1.88B
Sales Growth
+48.91% +45.26% +30.09% -26.56%
Cost of Goods Sold (COGS) incl D&A
1.11B 1.63B 2.31B 1.59B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
90.25M 123.42M 123.17M 115.85M
Depreciation
32.00M 32.40M 30.30M 26.30M
Amortization of Intangibles
35.20M 91.02M 88.07M 89.55M
COGS Growth
+54.08% +47.14% +41.80% -30.98%
Gross Income
246.39M 337.06M 247.88M 284.03M
Gross Income Growth
+29.43% +36.80% -26.46% +14.58%
Gross Profit Margin
+18.22% +17.16% +9.70% +15.14%
2022 2023 2024 2025 5-year trend
SG&A Expense
241.33M 306.27M 245.55M 288.47M
Research & Development
- - - -
-
Other SG&A
241.33M 306.27M 245.55M 288.47M
SGA Growth
+16.14% +26.91% -19.83% +17.48%
Other Operating Expense
- - - -
-
Unusual Expense
57.56M 176.88M 42.99M 439.86M
EBIT after Unusual Expense
(52.50M) (146.10M) (40.66M) (444.29M)
Non Operating Income/Expense
6.00M (2.10M) 2.34M (32.87M)
Non-Operating Interest Income
1.37M 5.26M 5.54M 4.19M
Equity in Earnings of Affiliates
4.57M 1.29M (3.44M) 365.00K
Interest Expense
15.57M 54.20M 24.72M 57.47M
Interest Expense Growth
-38.75% +248.09% -54.39% +132.47%
Gross Interest Expense
15.57M 54.20M 24.72M 57.47M
Interest Capitalized
- - - -
-
Pretax Income
(62.08M) (202.41M) (63.04M) (534.64M)
Pretax Income Growth
-108.31% -226.05% +68.86% -748.14%
Pretax Margin
-4.59% -10.31% -2.47% -28.50%
Income Tax
(43.38M) (89.36M) (1.41M) (126.00K)
Income Tax - Current - Domestic
(47.05M) (35.93M) 15.96M 13.35M
Income Tax - Current - Foreign
1.32M 1.03M 1.45M 1.51M
Income Tax - Deferred - Domestic
2.27M (54.98M) (18.78M) (14.68M)
Income Tax - Deferred - Foreign
92.00K 510.00K (49.00K) (305.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
4.57M 1.29M (3.44M) 365.00K
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.70M) (113.04M) (61.62M) (534.51M)
Minority Interest Expense
- - - -
-
Net Income
(18.70M) (113.04M) (61.62M) (534.51M)
Net Income Growth
+38.25% -504.46% +45.49% -767.39%
Net Margin Growth
-1.38% -5.76% -2.41% -28.49%
Extraordinaries & Discontinued Operations
- - - 37.00K
-
Discontinued Operations
- - - 37.00K
-
Net Income After Extraordinaries
(18.66M) (113.04M) (61.62M) (534.51M)
Preferred Dividends
- 29.22M 31.83M 44.89M
Net Income Available to Common
(18.66M) (142.26M) (93.45M) (579.40M)
EPS (Basic)
-0.1992 -1.2787 -0.8149 -5.0732
EPS (Basic) Growth
+44.34% -541.92% +36.27% -522.55%
Basic Shares Outstanding
93.70M 111.25M 114.68M 114.21M
EPS (Diluted)
-0.1992 -1.2787 -0.8149 -5.0732
EPS (Diluted) Growth
+44.34% -541.92% +36.27% -522.55%
Diluted Shares Outstanding
93.70M 111.25M 114.68M 114.21M
EBITDA
95.31M 154.20M 125.50M 111.42M
EBITDA Growth
+123.64% +61.79% -18.61% -11.22%
EBITDA Margin
+7.05% +7.85% +4.91% +5.94%

Snapshot

Average Recommendation BUY Average Target Price 5.75
Number of Ratings 15 Current Quarters Estimate -0.012
FY Report Date 06 / 2026 Current Year's Estimate 0.174
Last Quarter’s Earnings -0.02 Median PE on CY Estimate N/A
Year Ago Earnings 0.09 Next Fiscal Year Estimate 0.385
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 12 11 13
Mean Estimate -0.01 0.05 0.17 0.38
High Estimates 0.01 0.09 0.26 0.71
Low Estimate -0.05 0.00 0.05 0.16
Coefficient of Variance -151.94 52.09 36.51 36.56

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 14 14
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Evolent Health Inc in the News